Komori
OncoTherapy Science (4564) · InitiativeFirst stated

Evaluation and applied research on a liquid-biopsy platform with Thermo Fisher Scientific

First written in FY2018. . Latest entry: FY2018.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Advancing Personalized Healthcare and Cancer Genomic MedicineA theme 4 companies write about · 0 as a headwind · 10 as a tailwind

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2018First statedAnnual report

    「CPM has partnered with Thermo Fisher Scientific and is evaluating the liquid biopsy platform launched by Thermo Fisher Scientific.」

    CPM began evaluating a platform using the Ion Torrent™ Oncomine™ Pan-Cancer Cell-Free Assay and conducting applied research into the early detection of cancer with Thermo Fisher Scientific.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Evaluation and applied research on a liquid-biopsy platform with Thermo Fisher Scientific | OncoTherapy Science,Inc. (4564) | Komori